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This study investigates 3 amorphous technologies to improve the dissolution rate and oral bioavailability
of ﬂubendazole (FLU). The selected approaches are (1) a standard spray-dried dispersion with hydrox-
ypropylmethylcellulose (HPMC) E5 or polyvinylpyrrolidone-vinyl acetate 64, both with Vitamin E d-a-
tocopheryl polyethylene glycol succinate; (2) a modiﬁed process spray-dried dispersion (MPSDD) with
either HPMC E3 or hydroxypropylmethylcellulose acetate succinate (HPMCAS-M); and (3) conﬁning FLU
in ordered mesoporous silica (OMS). The physicochemical stability and in vitro release of optimized
formulations were evaluated following 2 weeks of open conditions at 25C/60% relative humidity (RH)
and 40C/75% RH. All formulations remained amorphous at 25C/60% RH. Only the MPSDD formulation
containing HPMCAS-M and 3/7 (wt./wt.) FLU/OMS did not crystallize following 40C/75% RH exposure.
The OMS and MPSDD formulations contained the lowest and highest amount of hydrolyzed degradant,
respectively. All formulations were dosed to rats at 20 mg/kg in suspension. One FLU/OMS formulation
was also dosed as a capsule blend. Plasma concentration proﬁles were determined following a single
dose. In vivo ﬁndings show that the OMS capsule and suspension resulted in the overall highest area
under the curve and Cmax values, respectively. These results cross-evaluate various amorphous formu-
lations and provide a link to enhanced biopharmaceutical performance.
© 2016 The Authors. Published by Elsevier Inc. on behalf of the American Pharmacists Association®. This
is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).pharmaceutical ingredient;
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Studies indicate that drug candidates are becoming increasingly
difﬁcult to formulate as a function of 3 conﬂuent trends: (1) the use
of high throughput screening to identify drug leads; (2) the nature
of drug candidate isolation from chemical processes, which biases
systems to complex forms; and (3) the nature of contemporary
drug targets, which often diverge from the chemical space that is
known to provide useful oral bioavailabilities.1,2 Although con-
ventional formulation strategies are initially sought based on their
lower developmental risk and cost, often these approaches do not
provide for adequate exposure in preclinical and clinical assess-
ments. There is a strong industrial sensitivity toward aggregating
the risk of new drug delivery systems. Therefore, the aim of thisrmacists Association®. This is an open access article under the CC BY license (http://
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emerging drug delivery technologies with a more conventional
approach as a performance-based drug development risk assess-
ment with ﬂubendazole (FLU) as the model compound.
FLU belongs to the group of benzimidazole carbamates and was
ﬁrst marketed as Fluvermal® by Janssen Pharmaceutica in the mid-
1970s as an anthelminthic agent against gastrointestinal parasites.
In an early 1980s study in Mexico, FLU demonstrated superior
activity compared with diethylcarbamazine against the ﬁlarial
parasite, Onchocerca volvulus, after 12 months of follow-up.3
Although this study had some limitations (i.e., the total exposure
from 5 weekly injections was not assessed), the activity of FLU was
supported by the absence of recurrent dermal microﬁlaria, a
surrogate marker for living worms capable of reproduction. It was
recently estimated that 26 and 129 million people (mainly in sub-
Saharan Africa) are infected with the ﬁlarial diseases onchocerci-
asis and lymphatic ﬁlariasis, respectively.4,5
As Fluvermal was originally designed to treat gastrointestinal
parasites, systemic uptake was not required. Also, it is well known
that orally administeredmethylcarbamate benzimidazole results in
poor systemic exposure in most species.6 Therefore, the ﬁrst step
was to re-formulate FLU to improve the dissolution rate, solubility,
and therefore the systemic exposure, which is necessary to target
the ﬁlarial larvae and adult worm. Here, we evaluate 3 amorphous
drug delivery technologies to achieve this.
Solid dispersions were ﬁrst deﬁned in 1971 as one or more
active ingredients in an inert carrier or matrix in the solid state.7
Due to advances in manufacturing process technologies, solid dis-
persions are now routinely produced by spray drying as a means to
enhance the dissolution rate and solubility of poorly soluble com-
pounds.8 Here, the resulting active pharmaceutical ingredient (API)
is molecularly dispersed within the polymeric carrier matrix.8-10
Following exposure to aqueous media, the API is released in its
supersaturated state as individual molecules and/or ﬁne colloidal
particles and the polymeric carrier impedes precipitation, leading
to its enhanced performance.9,11,12 Examples of marketed solid
dispersions include Sporanox® and Kaletra®.
One limitation of this technique is that both the API and polymer
must be soluble in the liquid phase. Because this solventmust easily
evaporate for particle formulation to occur, a low vapor pressure is
also necessary. For compounds with low solubility in solvent
systems that meet the previously mentioned criteria, or to avoid
non-compendial solvents, heat can be used to increase the solu-
bility. The level of heat that is required for total solubilization
depends on many factors. For compounds with solubility limita-
tions similar to FLU, an in-line heat exchanger can be used to heat
the sample above the boiling point of the solvent. The in-line heat
exchanger technology was chosen based on the very limited
exposure (<30 s) that is required to completely dissolve the API.
Using heat to increase solubility in volatile organic solvents has
associated risks. Particle size and morphology of the ingoing API
can have an effect on the dissolution kinetics during heating and
can require longer residence times in the heat exchanger. Chemical
stability during heating is also a consideration. However, due to the
limited time the spray solution is exposed to the elevated tem-
perature, thermal chemical degradation is typically not observed.
Once the API has been dissolved in the heat exchanger, a specialized
atomizer (termed a ﬂash nozzle) is used. This nozzle is unique to
the heating process based on atomization taking place by ﬂash
boiling of the solvent.13,14
Adsorption onto ordered mesoporous silica (OMS) is another
example of a new enabling technology that improves the perfor-
mance of poorly soluble compounds by improving their dissolution
rate and solubility and thereby enhancing oral bioavailability.15-17 It
is increasingly attracting the attention of industrial scientists due toseveral factors such as its burgeoned interest in the academic
world.18,19 Their cylindrical and uniform-sized pore structure
serves as the key attribute to improve the dissolution rate of poorly
soluble compounds. A concentrated drug solution is loaded into the
pores through capillary forces. The dissolved API is added in cycles
to allow solvent evaporation, leading to a conﬁned amorphous
API.20 When the mesopore size is only a few times larger than the
drug molecule, the conﬁned API is unable to crystallize, thus
exhibiting a higher free energy and consequently higher solubility
when compared to its crystalline counterpart.21,22
Formulations from each drug delivery technology were
screened using a variety of solid-state characterization tools and
in vitro dissolution experiments in biorelevant media. The physical
and chemical stability of the formulations following 2 weeks of
open storage at 25C/60% RH and 40C/75% RH was also assessed.
Finally, the 2 lead formulations from each amorphous technology
were selected to evaluate systemic exposure in rats. The results
from this study provide further insight into industrial formulation
considerations of these emerging technologies while linking them
to their in vivo performance.
Materials and Methods
Powder Manufacturing
Standard Spray-Dried Dispersions
The feedstock solution was prepared by dissolving either a
1/9/0.5 or 1/3/0.15 weight ratio of FLU (Shaanxi Hanjiang
Pharmaceutical Group, Hanzhong City, China)/polymer/Vitamin E
d-a-tocopheryl polyethylene glycol 1000 succinate (TPGS; Barentz
NV, Zaventem, Belgium) in 1/9 (wt./wt.) 98%-100% formic acid (FA;
Merck, Overijse, Belgium)/dichloromethane (DCM; Merck). The
selected polymers were either hydroxypropylmethylcellulose
(HPMC E5; Dow Chemical, Terneuzen, The Netherlands) or
polyvinylpyrrolidone-vinyl acetate 64 (PVP VA 64; Kollidon®64,
BASF, Ludwigshaven, Germany). A Büchi 290 (Flawil, Switzerland)
equipped with an inert loop was used to spray dry in closed loop
conditions with an inlet and outlet temperature of 65C and 45C,
respectively, and a spray rate of 8 g/min under nitrogen ﬂow. The
damp powder was removed from the collector and dried20 h in a
vacuum oven (Heraeus, Liederkerke, Belgium) set to 45C and 200
mbar under nitrogen ﬂow. To investigate the inﬂuence of drying
time, the 1/3/0.15, FLU/HPMC E5/Vit. E TPGS was also dried for 5
days under the same conditions.
Modiﬁed Process Spray-Dried Dispersions
The stock suspension was prepared by suspending FLU and
polymer in the appropriate solvent systems at the various
ratios of FLU/polymer. Formulations containing hydrox-
ypropylmethylcellulose acetate succinate-M (HPMCAS-M; Shin-
Etsu, Tokyo, Japan) were suspended in 9:1 acetone:water
(Honeywell Burdick & Jackson, Muskegon, MI) and formulations
containing HPMC E3 (Dow Chemical, Midland, MI) were sus-
pended in 9:1 methanol:water (Honeywell Burdick & Jackson).
The approach for ensuring complete dissolution of the API in
this spray-drying process is 2-fold. First, the solubility for the
given solvent system and temperature is previously determined
prior to the modiﬁed spray-drying process. To ensure dissolu-
tion, a process temperature that is slightly higher than the
temperature at which the solubility was observed is selected.
Second, the lack of crystalline material present in the ﬁnal
dispersion is evidence that complete dissolution of the API was
achieved in the heat exchanger. The material was prepared by
spray drying using a modiﬁed spray dryer similar in scale to a
ProCepT (Zalzate, Belgium). The spray-drying equipment was
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exchanger operating at 120C-130C. These formulations were
spray dried at a solvent ﬂow rate of 25 g/min with an outlet
temperature of 45C-55C. The wet MPSDD (modiﬁed process
spray-dried dispersion) powder was placed in a convection tray
dryer at 40C and ambient humidity for 19.5 h.
Ordered Mesoporous Silica
OMS synthesis was based on the procedure described by Jam-
maer et al.23 Two solvent systems were used to load FLU into OMS
containing 7-nm diameter pores using the incipient wetness
impregnation method.20 A target drug load of 2/8 (wt./wt.) FLU/
OMS was prepared using a 100 mg/mL solution of FLU in 1/1 (vol./
vol.) FA (Chem-Lab, Zedelgem, Belgium)/DCM (Fisher Scientiﬁc,
Aalst, Belgium).
Pure FAwas used to dissolve 200 mg/mL FLU in order to achieve
3/7, 4/6, and 1/1 (wt./wt.) FLU/OMS. The damp material was post
dried in a Binder VD53 vacuum oven (Tuttlingen, Germany) set to
40C at a reduced pressure of 50 mbar for 20 h.
In Vitro Characterization
Powder X-Ray Diffraction
The solid-state nature of FLU was determined by powder X-ray
diffraction (PXRD) in reﬂection mode using an X’PertPRO diffrac-
tometer (PANalytical, Eindhoven,TheNetherlands) equippedwith an
X’Celerator detector and spinner stage. Samples were ﬂattened onto
zero background plate holders andmeasured in ambient conditions
by scanning from3 to 50 2qwith a 0.0167 2q step size every 60 s in
reﬂection mode with a 1 s spinner revolution time. CuKa radiation
(1.5406Å)wasusedwithageneratorvoltageandcurrentof45kVand
40 mA, respectively. Diffraction patterns were analyzed using the
X’Pert High Score Plus version 2.2a (PANalytical) software.
Modulated Differential Scanning Calorimetry
MPSDD was evaluated by modulated differential scanning
calorimetry (mDSC) to determine the thermal characteristics of the
formulations. These formulations were evaluated on TA Q1000
mDSC (New Castle, DE) with sub-ambient cooling system and TA
Universal Analysis software. Samples were prepared as 5-mm
compacts and equilibrated overnight at <5% RH. Samples were
analyzed using method parameters of 20C to 180C at a rate of
2.5C/min with a modulation of ±1.5C/min.
In Vitro Dissolution
All in vitro dissolution tests were evaluated as suspensions for
ease of comparison to the in vivo results (Section 2.3). Prior to
dissolution testing, formulations equivalent to 50 mg API were
prepared as a suspension in 0.5 wt.% Methocel (DOW Europe
GmbH, Antwerpen, Belgium) containing a 2 mg API/mL concen-
tration. Suspensions were prepared immediately prior to dissolu-
tion by ﬁrst weighing an amount of formulation equal to the dose of
50 mg of API into a 20-mL syringe. The 4/6 FLU/OMS formulation
was also tested as a capsule blend, which contained 33% FLU, 49%
OMS, 8% sodium lauryl sulfate (BASF), and 10% Ac-Di-Sol® (FMC,
Cork, Ireland) weight ratio. The blend was homogenized using a
mortar and pestle and placed into a size 000 HPMC capsule
(Capsugel, Bornem, Belgium). The dissolution test was performed
using a paddle apparatus USP type 2 (Erweka DT 12, Hausenstamm,
Germany) at 75 rpm. A 2-phase biorelevant media simulating the
human fed condition was selected to evaluate the in vitro release
performance. The ﬁrst phase consisted of 300 mL of 0.05-M sodium
phosphate buffer pH 4.9 containing 0.2% of sodium chloride. After
60 min, a second phase of 600 mL of concentrated fed state simu-
lated intestinal ﬂuid (FeSSIF) was added to the vessel and stirred foran additional 2 h. Samples were collected at pre-determined time
points in each phase and immediately ﬁltered. The samples were
diluted 1:9 in 1/1 (vol./vol.) N,N-dimethylformamide (Sigma-
Aldrich)/water prior to analysis using ultra performance liquid
chromatography (UPLC).
Microcentrifuge dissolution tests were conducted as a screening
tool for the MPSDD formulations only. This test measures the super-
saturation of drug above the API crystalline solubility when dosed as
loose powder or a suspension into biorelevant media. The drug con-
centrations measured in this test were a composite of MPSDD free
drug, drug in micelles, and drug suspended in solution as drug/poly-
mer colloids. The gastric-transfer microcentrifuge dissolution test
assesses the impact of dissolution after exposure to a low-pH envi-
ronment. During the test, samples are transferred from gastric buffer
[0.01N HCl, pH 2.0 (theoretical Cmax ¼ 1000 mgA/mL)] to simulated
intestinal ﬂuid [FaSSIF, pH 6.5 (theoretical Cmax ¼ 500 mgA/mL)]. An
ultracentrifuge samplewas also taken at either 90min or 1200min to
measure the concentration of free drug plus drug in micelles.
Scanning Electron Microscopy
MPSDD was analyzed for particle morphology by a Hitachi
Model S-3400N Scanning Electron Microscope (Krefeld, Germany).
Samples were placed on a new aluminum post using adhesive tabs
and were lightly spread. Care was taken to ensure the particles
were not crushed or altered during sample preparation. Samples
were sputter coated in a Hummer 6.2 sputter coater with AuPd
target. MPSDD was then imaged at multiple magniﬁcations to
assess surface morphology.
Chromatography
High Performance Liquid Chromatography. Assay and chemical
purity were quantiﬁed using a high performance liquid chroma-
tography (HPLC) system (Waters Alliance 2695, Zellik, Belgium)
consisting of a quaternary pump with gradient portion valve
equipped with a 100 mL loop. The W2996 PDA detector was set to
248 nm. The mobile phase consisted of (A) 25 mM ammonium ac-
etate (NH4Ac; Sigma-Aldrich) adjusted to pH 9 with ammonium
hydroxide (Sigma-Aldrich) and (B) acetonitrile (ACN; Merck).
Gradient elution at a constant ﬂow rate of 1 mL/minwas performed
as follows: 70% of (A) decreased linearly to 66% in 2min, followed by
another linear decrease to 60%at 14min andheld constant for 1min.
Following 15 min, (A) increased linearly to 70% and held constant
until 20 min. A 5-mL injection volume ﬂowed through an X-Bridge
C-18, 150  4.6-mm column (Waters) set to a temperature of 30C.
Reference solutions were injected n  5 and were linear over the
concentration range of 0.05-0.5 mg/mL. Samples were injected as
n ¼ 1. Peaks were integrated using the Empower 3 software.
The suspensions prepared for in vivo dosing were also evaluated
for concentration and homogeneity using HPLC-UV (Shimadzu
lC20AD), consisting of a pump, oven, degasser, and Communication
Bus Module. The ultraviolet detector was set to 235 nm. The sam-
ples were diluted in methanol (Merck)/1N HCl (90/10, vol./vol.) and
10 mL was injected through an XTerra RP C-18 column, 100  4.6
mm (Waters) set to a temperature of 35C. The ﬂow rate was
constant at 1.5mL/min. A linear gradientmethodwas used: initially
9/1 (vol./vol.) of 0.1% wt./vol. NH4Ac (Sigma-Aldrich) in water/ACN
to 0/10 (vol./vol.) 0.1% wt./vol. NH4Ac in water/ACN after 10 min.
This was followed by a 5-min purge with 100% ACN. The limit of
quantiﬁcation and limit of detection values of this validated
method are 0.22 and 0.065 mg/mL, respectively.
Ultra Performance Liquid Chromatography. Drug release following
in vitro dissolution was quantiﬁed using an UPLC equipped with a
ultraviolet detector (Waters, H-Class) set to 280 nm. The selected
mobile phase was 3/7 (vol./vol.) ACN (Merck)/0.1% triﬂuoroacetic
Figure 1. Structure of ﬂubendazole (FLU) and its 2 metabolites.
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2-mL injection volume ﬂowed through an Acquity UPLC® BEH C-18,
50  2.1 mm column (Waters) set to a temperature of 35 ± 5C
during the 1.2-min run time. A reference solution (0.0556 mg/mL)
of N,N-dimethylformamide (Sigma-Aldrich) and a diluted reference
solution (0.00556 mg/mL) of FLU in 1/1 (vol./vol.) water/N,N-
dimethylformamide were prepared in duplicate. The diluted
reference solution 1 was injected n ¼ 5 as the calibration standard.
The diluted reference solution 2 was injected n ¼ 2 as a control. An
n ¼ 2 injection of diluted reference solution 1 was performed after
12 injections and after the last injection as a control. Test samples
were injected as n ¼ 2. The reported results as percent dissolved
were calculated based on the n ¼ 5 injections from the ﬁrst diluted
RS (0.00556 mg/mL). Peaks were integrated using the Empower 2
and 3 software.
Gas Chromatography. Residual FA was determined using gas chro-
matography (GC 7890A, Agilent, Diegem, Belgium) coupled to a
ﬂame ionization detector. Chromatographic separation was
achieved using a 0.18 mm  20 m fused silica column (Rxi-624MS)
of 1-mm ﬁlm thickness. Injector and detector temperatures were set
to 260C and 270C, respectively. A constant H2 gas ﬂow was set to
1 mL/min. The oven program used was in 2 steps: (1) starting
temperature 45C held for 0.2 min, ramp 2C/min up to 50C, and
(2) ramp 35C/min to 250C and held for 1.60 min (total run time of
10min). Samples were prepared by transferring the content of 5mg
API in a 10-mL headspace vial and adding 2.5 mL dilution solvent
containing 1/9 (vol./vol.) 1-propanol (Acros, Geel, Belgium)/
dimethyl sulfoxide (Sigma-Aldrich, Diegem, Belgium) and 0.5-mL
sulfuric acid (Merck). Concentration was determined based on a
1-point calibration curve on 5000 ppm.
DCM was analyzed by GC (EDMS-ERI-7845511:2.0, Agilent)
coupled to a ﬂame ionization detector. Chromatographic separation
was achieved using a 0.32 mm  50 m fused silica column, coated
with chemically bonded polydimethylsiloxane phase (CP-SIL 5 CB)
of 5-mm ﬁlm thickness. Injector and detector temperatures were set
to 230C and 270C, respectively. A constant N2 gas ﬂow was set to
25 mL/min. The oven program used was in 2 steps: (1) starting
temperature 40C held for 0.5 min, ramp 5C/min up to 170C, (2)
ramp 30C/min to 220C and held for 11.83 min. Samples were
prepared by dissolving 25 mg of API in 2 mL of 1,3-dimethyl-2-
imidazolinone (Sigma-Aldrich) in a 22-mL gas-tight vial. Concen-
tration was determined based on a 3-point calibration curve
ranging from 0.98 to 24.59 mg/mL.
Liquid ChromatographyeTandem Mass Spectrometry. Plasma sam-
ples were prepared by protein precipitation (ACN) and the super-
natant was diluted with 0.1% FA inMilli-Q water/ACN (8/2 vol./vol.).
The stable isotope labeled FLU-d3 (Sigma-Aldrich) was used as the
internal standard. Samples were then analyzed by liquid
chromatographyetandem mass spectrometry in the range of 5-
5000 ng/mL. The system consisted of a Turbo-Ionspray™ interface
(in positive mode) coupled with a Shimadzu liquid chromatogram
(LC20AD, Brussels, Belgium). The LC system was equipped with a
pump, oven, communication bus module, and degasser. The chro-
matographic separation was established on a 5 cm  2.1-mm col-
umn, packed with 3.5 mm X-Bridge C18 (Waters) operating at 30C.
A gradient elution started at ACN/0.1% FA in Milli-Q water (50/50
vol./vol.) and completed at 98/2 vol./vol. The multiple reaction
monitoring transitions were captured at 314.1-282 and 317.1-282.
N2 Physisorption
Nitrogen adsorption isotherms of all OMS materials were
measured at196C using aMicrometrics Tristar II 3020-apparatus
(Brussels, Belgium). Samples were pre-treated for 2 h at 30C undera nitrogen ﬂush. The pore volume and the surface area were
calculated using the Brunauer-Emmett-Teller theory. Themesopore
size distribution was derived from the desorption isotherm branch
using the Barrett-Joyner-Halenda model.
In Vivo Experiments
All in vivo studies were performed in accordance with the
European Directive 2010/63 and Belgian laws regarding the pro-
tection of laboratory animals. Male Sprague-Dawley rats were given
access to food and water ad libitum. An oral dose of 20 mg/kg was
administered as either a suspension or capsule blend. Crystalline
FLU was administered to 200-300 g rats as a micro- and nano-
suspension. Microsuspensions containing 2 mg/mL FLU were pre-
pared with 1 mg/mL docusate sodium (Cytec Industries BV,
Vlaardigen, The Netherlands), 12 mg/mL Avicel® RC591 (FMC In-
ternational, Cork, Ireland), 20 mg/mL PVA 17 (BASF), 10 mg/mL
Aqualon® sodium carboxymethylcellulose (Ashland, Sint-Gillis-
Waas, Belgium), 1.8 mg/mL methylparaben (Merck), and 0.2 mg/
mL propylparaben (Merck). Nanosuspensions also containing 2mg/
mL FLU were prepared with 0.5 mg/mL Poloxamer 338 (BASF) and
0.05 mg/mL docusate sodium. Amorphous suspensions containing
either standard spray-dried dispersion (SSDD), MPSDD or 3/7 (wt./
wt.) FLU/OMS were prepared with 0.5-wt.% Methocel immediately
prior to dosing. The OMS formulation was administered both as a
suspension and capsule blend. The 4/6 (wt./wt.) FLU/OMS was the
only formulation capable of ﬁtting the target dose into one capsule.
Moreover, it was postulated that the suspension vehicle would
quickly enter the mesopores and push the API into the surrounding
media, thus leading to rapid precipitation prior to dosing.24 Capsule
blends were prepared according to the speciﬁc weight of each rat
(325-355 g) following the blend ratios previously described (section
2.2.3) and placed into a size 9 elongated capsule (Torpac, Fairﬁeld,
NJ). Blood samples (60 mL) were collected from the lateral tail vein at
t ¼ 0.5, 1, 2, 4, 7, and 24 h after dosing. Samples were centrifuged at
1500  g (Hettich, Tuttlingen, Germany) for roughly 10 min in
ambient conditions within 1 h after sampling. Plasma samples after
dosing were analyzed by liquid chromatographyetandem mass
spectrometry. A non-compartmental pharmacokinetic (PK) analysis
Table 1
Physicochemical Properties of Flubendazole (FLU)
Characteristic Value
Molecular weight (g/mol) 313.1
Tm (C) 238
Tg (C) 156
pKa 3.6 and 9.6
LogP 3
Papp (10 mM) AB: 33.8  106 cm/s
Solubility (mg/mL) in ambient conditions
Water 0.005
Methanol 0.11
Acetone 0.18
Dichloromethane 0.14
Formic acid 340
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plasma concentrations (Cmax) and corresponding peak times (Tmax)
were calculated. The area under the plasma concentrationetime
curve from time zero to time t (AUC0-t), where t is the sampling
time corresponding to the last measurable concentration above the
lower limit of quantiﬁcation, and from time zero to inﬁnity (AUC0-
inf) were calculated using the linear up/log down trapezoidal rule.Results
The structure of FLU and its 2 metabolites, the hydrolyzed and
reduced forms, are illustrated in Figure 1. The carbamate group is
the main source of FLU’s extremely low aqueous solubility of 5 ng/
mL (Table 1).Development Challenges With FA
As shown in Table 1, FLU also exhibits very low solubility in
common organic solvents, but a very high solubility in FA, which
ionizes the carbamate group (pKa 3.6) to increase the solubility. For
successful employment of SDD and OMS technologies, a suitable
concentration of dissolved API is required. Moreover, the selected
solvents ideally exhibit a low vapor pressure for adequate removal
following processing (SDD) or drug loading (OMS). Although a
small amount of FA is sufﬁcient to signiﬁcantly improve theFigure 2. PXRD patterns (a) 2/8, (b) 3/7, (c) 4/6, and (solubility, one major challenge is the elimination of residual FA due
to its relatively high boiling point (~101C).25OMS Drug Loading
Due to its low volatility, DCM is a favorable solvent for OMS drug
loading. However, the addition of FA was necessary in order to
achieve a concentrated FLU solution necessary for drug loading
(Table 1). A 1/1 (vol./vol.) FA/DCM solution was selected to load the
2/8 (wt./wt.) FLU/OMS. Pure FA was necessary to increase the drug
load, as determined during early drug loading development studies.
Figure2 illustrates thePXRDpatternsof2/8, 3/7, 4/6, and1/1 (wt./wt.)
FLU/OMS. The presence of small Bragg peaks following 1/1 (wt./wt.)
FLU/OMSdrug loading corresponds to crystalline FLU. Assuming that
mesopore-associated API is amorphous as a result of conﬁnement
effects, Bragg peaks in the sample suggest that some API is located
outsideof themesopores.26 Therefore, no further investigationswere
conducted with the 1/1 (wt./wt.) FLU/OMS formulation.
The nitrogen physisorption results (Fig. 3) before and after drug
loading reveal an overall decrease in available pore volume with an
increase in drug load (Fig. 3a). A 740 cm3/g total volumewas initially
determined and decreased to approximately 350 cm3/g following
40% weight drug loading. Likewise, as seen in Figure 3b, the pore
volumeandpore sizedecreasedasdrug load increased,bothofwhich
indicate that the API is loaded inside the mesoporous structure.SSDD Process
As with the OMS formulation, FA was necessary to increase the
solubility required for spraydrying. Based onan internallydeveloped
spray dry model, a feedstock concentration of 1/9 (wt./wt.) FA/DCM
was calculated as suitable for the equipment and working safety. A
high and low API concentration of 1/9/0.5 or 1/3/0.15 FLU/polymer/
Vit. E TPGS wt. ratio was selected to bracket the concentrations that
were initially evaluated. Vit. E TPGS was selected as a precipitation
inhibitor, based on automated screening experiments. The chemical
structure of selected polymers is shown in Figure 4. PVP VA 64 was
selected based on results from early developmental studies and
HPMC E5 is a preferred polymer for spray dry experiments. Based on
PXRD results, samples prepared with HPMC E5 and PVP VA 64 were
amorphous and partially crystalline (Fig. 5). Based on these results,
SSDD development was only continued with HPMC E5 samples.d) 1/1 FLU/OMS (wt./wt.) following drug loading.
Figure 3. (a) Nitrogen adsorption/desorption isotherm and (b) Barrett-Joyner-Halenda determined pore diameter distribution of OMS before and after drug loading. All ratios
expressed in weight.
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GCwas used to determine the residual amount of FA and DCM in
FLU-loaded OMS and SSDD. The detected DCM concentration was
below the reporting threshold of 50 ppm in all formulations. The
residual FA concentrations are shown in Figure 6. For the OMS
concept, the FA concentration signiﬁcantly increases with
increasing drug load. The large increase from 4000 ppm (2/8 FLU/
OMS) to 21,000 ppm (3/7 FLU/OMS) is attributed to the additional
amount of FA required to increase the drug loading. To investigate
the inﬂuence of drying time, SSDD 1/3/0.15, FLU/HPMC E5/Vit. E
TPGS wt. ratio was measured following overnight and 5-day post
drying. Here, no decrease in residual FA was observed following 5
days drying. There was, however, a small decrease (~2%) in assay, as
determined by HPLC (data not shown).Spray Dry Process Modiﬁcations
This approach uses a ﬂash nozzle, rather than a pressure swirl or
twin-ﬂuid atomizers as with a standard spray dry operation. Here,Figure 4. Chemical structure of polymers selected for SSDD and MPSDD (top) HPMC,
where R is either hydroxyl, methoxyl, 2-hydroxypropoxyl; (middle) HPMCAS, where R
represents either hydroxyl, methoxyl, 2-hydroxypropoxyl, acetyl, or succinoyl; (bot-
tom) PVP VA64, where n ¼ 1.2 m.atomization occurs via boiling of the solvent as it rapidly de-
pressurizes to ambient conditions. Based on the Gibbs-Helmholtz
equation (Eq. 1), the incorporation of heat increases the solubility
of FLU in commonly used spray dry solvents and bypasses the need
for FA. The resulting powder from these adaptations is described
here as an MPSDD.

vG=T
vT

p
¼  H
T2
(1)
Amorphicity of MPSDD was veriﬁed using PXRD (data not
shown) and mDSC (Fig. 7). Formulations were equilibrated over-
night (<5% RH) prior to mDSC measurements. The thermograms
reveal a single Tg, verifying a molecular dispersion. MPSDD pre-
pared with HPMCAS-M resulted in a Tg of approximately 109C
and 103C for 1/9 and 2.5/7.5 (wt./wt.) FLU/HPMCAS-M, respec-
tively. MPSDD prepared with 1/9 (wt./wt.) FLU/HPMC E3 resulted
in a slightly higher Tg of 120C. Based on the slower release
behavior from early development microcentrifuge dissolution
tests (see Supplementary Data), the 2.5/7.5 (wt./wt.) FLU/
HPMCAS-M was not further evaluated. In general, all the formu-
lations dissolved in gastric medium to above the crystalline API
solubility and sustained supersaturation of total solubilized drug
species after a 1:1 transfer into simulated intestinal media. The 1/
9 (wt./wt.) FLU/polymer MPSDD provided a higher concentration
of total solubilized drug species than the 2.5/7.5 (wt./wt.)
HPMCAS-M, and for this reason, not chosen for progression to
in vivo studies.
Scanning electron microscopy was used to investigate the
resulting particle morphology of MPSDD powders. As pictured in
Figure 8, they exhibit a spherical and corrugated shape, similar to
that of a standard spray-dried dispersion with no appearance of
crystalline API.
Physicochemical Stability
The leading formulations from each amorphous concept were
placed in open dish containers and exposed at 25C/60% RH and
40C/75% RH and analyzed at t ¼ 0 and t ¼ 2 weeks. These
aggressive conditions were selected as a fast screening tool as part
of the in vitro evaluations. PXRD was used to assess physical sta-
bility. HPLC assay and purity were used to determine chemical
stability.
Physical Stability
As shown in Figure 9, all formulations were stable at 25C/60%
RH for up to t ¼ 2 weeks. However, both 1/3/0.15 and 1/9/0.5 (FLU/
HPMC E5/Vit. E TPGS) SSDD formulations began to crystallize after
2 weeks' exposure at 40C/75% RH. The 1/9 (FLU/HPMC E3)
Figure 5. PXRD patterns of SSDD: FLU/HPMC E5/Vit. E TPGS: (a) 1/9/0.5 and (b) 1/3/0.15; FLU/PVP VA 64/Vit. E TPGS: (c) 1/9/0.5 and (d) 1/3/0.15 following post drying. All ratios
expressed in weight.
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crystallization following 40C/75% RH exposure. However, the 1/9
(wt./wt.) FLU/HPMCAS-M remained amorphous following storage
in both conditions. These results indicate that the crystallization of
the 1/9 (wt./wt.) FLU/HPMC E3 was due to theweaker API-polymer
interaction rather than the modiﬁed spray dry process itself. One
additional consideration for the crystallization that was observed
for the HPMC E3 containing dispersion could be the effect of water
uptake and resulting decrease in Tg at elevated humidity
conditions.
Diffraction patterns of OMS formulations reveal that physical
stability depends on the drug loading. The 4/6 (wt./wt.) FLU/OMS
crystallized following 40C/75% RH conditions, whereas the 3/7
(wt./wt.) FLU/OMS remained amorphous.Chemical Stability
Figure 10a illustrates the chemical assay results. At t ¼ 0, the
assay values ranged from 95.7% (4/6 FLU/OMS) to 103.3% (1/9/0.5
FLU/HPMC E5/Vit. E TPGS). Following 2 weeks' exposure, this value
decreases approximately 1%-2% wt. for SSDD and MPSDDFigure 6. Residual FA following overnight post drying in SSDD, FLU/HPMC E5/Vit. E
TPGS (a) 1/9/0.5, (b) 1/3/0.15 and FLU/OMS, (c) 2/8, (d) 3/7, and (e) 4/6. All ratios
expressed in weight.formulations. The OMS-based concepts resulted in the largest
decrease of around 4% wt.
Purity results revealed that the main degradation peak observed
in all formulations was attributed to the hydrolyzed form.
Figure 10b illustrates the concentration of this hydrolyzed degra-
dant in all tested samples. MPSDD formulations resulted in the
highest initial hydrolyzed concentration. The 1/9 (wt./wt.) FLU/
HPMCAS-M resulted in over twice the concentration to that of
1/9 (wt./wt.) FLU/HPMC E3. The OMS concepts resulted in the
overall lowest hydrolyzed concentration with no signiﬁcant dif-
ference observed between 3/7 and 4/6 (wt./wt.) FLU/OMS. Formu-
lations from all amorphous concepts resulted in an increasing
concentrationwith increased stressed conditions. At t ¼ 0, the total
degradation products of HPMCAS-Mwas highest at 2.12 and lowest
for 4/6 (wt./wt.) FLU/OMS at 0.66.
In Vitro Release Behavior
The in vitro release behavior of leading formulations was eval-
uated in bi-phasic biorelevant media to simulate the human fed
stomach into the fed intestine situation (Fig. 11). Both OMS for-
mulations resulted in the lowest overall release behavior in pH 4.9
and FeSSIF. The slightly higher release rate from the OMS suspen-
sion could be attributed to the faster ingress of media into the pores
and therefore faster release into the surrounding media. The SSDD
formulation containing 1/9/0.5 FLU/HPMC E5/Vit. E TPGS wt. ratio
maintained an overall similar release proﬁle in pH 4.9 and FeSSIF of
roughly 28%-35% dissolved. HPMCAS-M is a pH-dependent poly-
mer that begins to solubilize at pH >4.5. This is reﬂected in the
release behavior of MPSDD: 1/9 FLU/HPMCAS-M. An initial % dis-
solved of roughly 4% is observed in pH 4.9 then rapidly increases to
45% in FeSSIF, resulting in the overall highest amount of % dissolved
compared to all other formulations. However, the MPSDD
1/9 (wt./wt.) FLU/HPMC E3 performed slightly better than the SSDD
1/3/0.15, FLU/HPMC E5/Vit. E TPGS wt. ratio. Both OMS formula-
tions resulted in the overall lowest % dissolved in pH 4.9 and FeSSIF.
Poor wettability was visually observed with all formulation
concepts (i.e., poorly wetted powder remaining in the syringe)
and with the OMS capsule blend (i.e., particles sticking to the
sinker).
Figure 7. mDSC of MPSDD following manufacture.
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The plasma concentrationetime proﬁles of the FLU compound
are provided in Figure 12. As with the dissolution experiments,
poor wettability was again observed when preparing the suspen-
sions immediately prior to dosing. All amorphous concepts
formulated with polymer (SSDD and MPSDD) resulted in similar
Tmax values of 1.3-1.7 h (Table 2). The 3/7 (wt./wt.) FLU/OMS sus-
pension resulted in the fastest Tmax of 0.8 h and highest Cmax value
of 1220 ng/mL. The 4/6 (wt./wt.) FLU/OMS capsule blend plasma
proﬁle was distinct from all the other concepts. Although this
formulation had a later Tmax value of 2.4 h, it resulted in the overall
highest AUC0-24 h of 7800 ng$h/mL. Both crystalline suspensions
resulted in the slowest Tmax value of 3.0 h with the micro-
suspension exhibiting the overall lowest Cmax value of 102 ng/mL.
Compared to the microsuspension, the Cmax and AUC0-7 h value
of the nanosuspension increased 3-fold to 331 ng/mL and 1811
ng$h/mL, respectively.
Discussion
The objective of this study was to formulate amorphous FLU to
increase the dissolution rate and aqueous solubility to improve theFigure 8. Scanning electron microscopy micrographs of MPSDD (a) 1/9 FLU/HPMCAS-M, (systemic exposure. A 20-mg/kg dose was selected to compare the
in vivo behavior between the different formulations, as this is a
well-accepted dose level in the rodents to explore the PK. This
compound was ﬁrst developed for local activity against worms in
the gastrointestinal tract and therefore exploring the plasma levels
required for systemic exposure is still ongoing. Similarly, the rele-
vant dose in man for efﬁcacy and the desired shape of PK proﬁle is
under investigation.
Following oral administration in male rats, both crystalline
suspensions resulted in the latest Tmax of 3.0 h with the micro-
suspension exhibiting the overall lowest Cmax of 102 ng/mL.
Decreasing the particle size for the nanosuspension improved the
Cmax and AUC values by approximately 3-fold but these results were
still not sufﬁcient to increase the extent of supersaturation to
improve absorption. The 3/7 (wt./wt.) FLU/OMS suspension
exhibited the highest Cmax value, followed by a steady decline in
plasma concentration. This is due to its higher degree of super-
saturation upon release, coupled with no precipitation inhibitors.
Therefore, the compound is rapidly absorbed. The PK proﬁle of
the 4/6 (wt./wt.) FLU/OMS capsule blend resulted in the overall
highest AUC value of approximately 7800 ng$h/mL but a later Tmax
of 2.4 h. This difference in in vivo behavior is likely due to the dif-
ference in drug release kinetics from the capsule blend formulationb) 2.5/7.5 FLU/HPMCAS-M, and (c) 1/9 FLU/HPMC E3. All ratios expressed in weight.
Figure 9. PXRD patterns of SSDD: 1/9/0.5, 1/3/0.15, FLU/HPMC E5/Vit. E TPGS; MPSDD: 1/9 FLU/HPMC E3, 1/9 FLU/HPMCAS-M; OMS: 3/7, 4/6, FLU/OMS following 2 weeks' exposure
in open conditions and crystalline FLU. All ratios are expressed in weight and are listed from top to bottom in the diffraction proﬁles.
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ence in drug load. In the case of the capsule, time is required
for capsule disintegration and sodium lauryl sulfate in the blend
will contribute to increasing the extent of supersaturation. Both ofFigure 10. (a) Chemical assay and (b) hydrolyzed degradant as determined by HPLC followin
(c) 1/9, FLU/HPMCAS-M, (d) 1/9, FLU/HPMC E3; and FLU/OMS: (e) 3/7 and (f) 4/6. All ratiosthese will inﬂuence the shape of the plasma concentration time
proﬁle (Fig. 12).
In vitro dissolution was used as a tool to predict in vivo perfor-
mance. The biorelevant media was selected to simulate the fedg open conditions of SSDD: FLU/HPMC E5/Vit. E TPGS (a) 1/9/0.5, (b) 1/3/0.15; MPSDD:
expressed in weight.
Figure 11. Dissolution proﬁles of 2 mg/mL suspensions in 0.5%-wt. methocel and 4/6 FLU/OMS capsule blend. Formulations adjusted to 50 mg of API per dissolution vessel. Points
represent the average of n ¼ 2 and bars reﬂect the range. All formulation ratios expressed in weight.
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proﬁles did not correlate well with each other. These observed
differences could be attributed to a number of reasons. First, in vitro
conditions do not account for any gastrointestinal tract metabolism
and hydrodynamics that occur in vivo. Also, the biorelevant media
selected (pH 4.9-FeSSIF) does not accurately reﬂect the stomach
and intestinal tract pH conditions in rat, especially for pH-sensitive
polymers (i.e., HPMCAS-M).27
During the microcentrifuge dissolution test (Supplementary
Data), it was observed that the MPSDDs had a range of improve-
ment from 2 to 20 times that of the crystalline API, according to the
AUC. Based on the observed enhancement in the microcentrifuge
dissolution test, it is expected that these formulations would have a
range of enhancement when evaluated in the rodent. In general,
formulations are expected to have enhanced bioavailability relative
to the crystalline API.
Due to its high Tm of 238C (Table 1) and observed degradation
upon melting, a drug delivery technology that destroys the crystal
lattice by virtue of heating (i.e., hot melt extrusion) was not feasible.
A high amorphous drug load of <40% wt. with OMS containing a
pore size of approximately 6.6 nm (Fig. 3) was achieved due to its
high pore volume (~1 mL/g) and extremely large speciﬁc surface
area (~925 m2/g). These unique characteristics allow for high drug
loading capacity and potential for drug adsorption.28,29
Based on Flory-Huggins solution theory, miscibility and phase
behavior of SDDs is inﬂuenced by the API-polymer interaction.30 In
the case of SSDD, an amorphous solid dispersionwas achieved withFigure 12. Plasma concentrationetime proﬁle of FLU following oral administration (20 mg/k
deviation for suspensions and n ¼ 4 ± standard deviation for 4/6 (wt./wt.) FLU/OMS capsuHPMC E5 but not with PVP VA64, a co-polymer manufactured from
vinylpyrrolidone and vinylacetate monomers in blocks of 6 and 4
monomers, respectively (Fig. 4).31 This difference in ability to
interact between FLU and both polymers might be at the base of the
difference in ability to form an amorphous solid dispersion.
Another reason could be the difference in Tg between both poly-
mers, as HPMC has a higher Tg of ~145C compared to that of PVP
VA64 of ~107C.32-34 In contrast to PVP VA64, the ability for FLU to
form an amorphous solid dispersion with HPMC E5 suggests that
the use of a higher Tg excipient could make the API less prone to
recrystallization.
The use of FA to dissolve the API was also necessary with the
SSDD and OMS concepts. Although FA is placed in the safest cate-
gory of class III residual solvents, based on toxicity and degree of
environmental hazard, it still invites additional downstream pro-
cess challenge and considerations.35 The SSDD concepts were
produced in experimental scale equipment where the main com-
ponents are glass. Should this process need to be scaled up, the 1/9
(wt./wt.) FA/DCM solvent system may be incompatible with the
stainless steel metal components in commercial-scale spray dryers.
Similarly, careful attention to the equipment is required when drug
loading the OMS with both the 1/1 (vol./vol.) FA/DCM and pure FA
solutions.
Another downstream process concern is the removal of FA. The
International Conference of Harmonisation guidance for industry,
Q3C Impurities: Residual Solvent (ICS Q3C), limits FA to 5000 ppm
and a permitted daily exposure of 50 mg/day. As shown in Figure 6,g) to male Sprague-Dawley rats. Points represent the mean values of n ¼ 3 ± standard
le blend. All formulation ratios expressed in weight.
Table 2
PK Parameters of FLU Following a 20-mg/kg Dose
Formulation Cmax (ng/mL) Tmax (h) AUC0-7 h (ng$h/mL) AUC00-24 h (ng$h/mL) AUC0-∞ (ng$h/mL)
FLU microsuspension 102 ± 14.1 3.0 ± 1.73 575 ± 60.5 NC NC
FLU nanosuspension 331 ± 50.3 2.7 ± 1.15 1811 ± 347 2710 ± 347 3191 ± 690
1/9/0.5 FLU/HPMC E5/Vit. E TPGS 380 ± 89.7 1.3 ± 0.58 2300 ± 687 4030 ± 1320 4140 ± 1340
1/3/0.15 FLU/HPMC E5/Vit. E TPGS 320 ± 89.0 1.7 ± 0.58 1790 ± 489 3510 ± 952 3750 ± 990
1/9 FLU/HPMC E3 224 ± 51.3 1.7 ± 0.58 1230 ± 448 1940 ± 1110 2650 ± 562
1/9 FLU/HPMCAS-M 389 ± 97.3 1.3 ± 0.58 2110 ± 408 4320 ± 760 NC
4/6 FLU/OMS (capsule) 690 ± 359 2.4 ± 1.9 3240 ± 1820 7800 ± 5680 NC
3/7 FLU/OMS (suspension) 1220 ± 232 0.83 ± 0.29 3760 ± 317 5360 ± 287 5440 ± 290
Values represent the mean values of n¼ 3 ± standard deviation for suspensions and n¼ 4 ± standard deviation for 4/6 (wt./wt.) FLU/OMS capsule blend. All formulation ratios
expressed in weight. AUC extrapolation exceeds 25%.
NC, not calculated.
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5000 ppm limit. Although no formal drying studies were con-
ducted, it is unlikely that the residual FA in these OMS formulations
can be reduced signiﬁcantly when performing drug loading with
pure FA. The effect of drying time of 5 days in 45C and 200 mbar
under nitrogen ﬂow was investigated using one SSDD formulation
with no change in residual FA, albeit a small increase in chemical
degradation (data not shown). Based on results in Figure 10 and
FLU’s tendency to degrade upon heating, it is hypothesized that
increasing the drying temperature from 45C will also decrease the
chemical purity.
The use of heat during processing (MPSDD) circumvents the
need for FA, but resulted in a decrease in chemical purity. However,
the additional heat step is not the sole contributing factor to this.
The 1/9 (wt./wt.) FLU/HPMCAS-M resulted in over twice the
amount of hydrolyzed degradant compared to 1/9 (wt./wt.) FLU/
HPMC E3 (Fig. 10b). This is likely the result of HPMCAS-M acetate
succinate group interaction with the FLU’s hydrolysis-sensitive
carbamate group (Figs. 1 and 4). Although the OMS concept resul-
ted in highest chemical purity, it did result in the largest decrease in
assay following storage (Fig. 10a).
Although the 1/9 (wt./wt.) FLU/HPMCAS-M resulted in the
largest decrease in chemical purity, it was one of the most physi-
cally stable formulations following 40C/75% RH, together with 3/7
(wt./wt.) FLU/OMS. All formulations remained amorphous
following storage for 2 weeks at 25C/60% RH. During preliminary
evaluations of the MPSDD technology, the Tg following overnight
equilibration at <5%, 50%, and 75% RH was determined (data not
shown). As illustrated in Figure 7, the Tg of MPSDD prepared with
HPMC E3 is ~120C (<5% RH) but decreased to 60C following 75%
RH exposure. In the case of HPMCAS-M, the Tg equilibrated at <5%
RH is ~110C (Fig. 7) and decreased to 70C following 75% RH
conditions. These results show that HPMCAS-M takes up less water
than HPMC and is more effective in reducing the API’s molecular
mobility. Therefore, differences in moisture uptake can explain the
crystallization of 1/9 (wt./wt.) FLU/HPMC in 40C/75% RH, whereas
1/9 (wt./wt.) FLU/HPMCAS-M remained amorphous. The reason
that the 4/6 (wt./wt.) FLU/OMS showed signs of crystallization
while the 3/7 (wt./wt.) FLU/OMS did not is due to their difference in
drug load. Upon drug loading, the API is pulled into the pores
through capillary forces.20 Due to the silanol groups along OMS
walls, the drug’s tendency is to attach to the walls, rather than
accumulate in the center.26 Therefore, as the drug load increases,
the API begins to distribute toward the open end of the pores, thus
making it more susceptible to the external environment. The sta-
bility assessment in open conditions exposed FLU to harsh external
conditions not representative of a ﬁnished and packaged product.
Although the majority of formulations showed signs of crystallinity
following t ¼ 2 weeks at 40C/75% RH, this does not necessarily
mean that they are not developable. These aggressive conditionswere selected as part of our evaluation for selecting themost robust
amorphous formulation.Conclusions
Results from this study exhibit the process challenges in not
only formulating amorphous FLU but also stabilizing it. Formula-
tions from 3 different drug delivery technologies were explored
and optimized to improve the dissolution rate and extent of oral
absorption. Physicochemical stability and in vitro release in bio-
relevant media were used to screen all formulations. The 2
emerging drug delivery technologies, an MPSDD 1/9 (wt./wt.) FLU/
HPMCAS-M, and 3/7 (wt./wt.) FLU/OMS resulted in superior phys-
ical stability compared to the more conventional SSDD approach.
Although the OMS technology resulted in the best chemical purity,
the use of FA results in high amounts of residual solvent and
complicates downstream processability. The heat step during
MPSDD increased the amount of hydrolyzed degradant; however,
the results showed that this was also dependent on the API-
polymer interaction. Plasma concentration proﬁles from OMS for-
mulations differed due to the mode of administration between the
suspension and capsule blend. The 30% wt. loaded suspension
resulted in the fastest Tmax, highest Cmax, and exhibited an overall
distinctive proﬁle from the other concepts. The 40% wt. loaded
capsule blend resulted in the slowest Tmax and highest AUC.
Although the OMS illustrated promising in vivo performance, the
MPSDD technique will be further explored based on the in vitro
data and ease of manufacturing scalability.Acknowledgments
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